儿童间质性肺疾病幸存者成年期特征:欧洲协作研究
这项欧洲34个中心的研究报告了2023年1-7月儿童间质性肺疾病幸存者病例,共244例,中位诊断年龄12.5岁,入组时25岁。86%不吸烟,中位FVC%预计值70%,DLCO%预计值48%,32%长期氧疗,93%在成人中心随访。结论是幸存者肺功能显著受损,病因异质性对成人中心有实际影响。
要点
- 儿童间质性肺疾病幸存者多在成人中心随访,仅7%未转诊。
- 肺功能显著受损:中位FVC%预计值70%,DLCO%预计值48%。
- 60%仍在使用糖皮质激素,9.8%和16%转诊后诊断与治疗被重新指定。
核心结论
- 儿童间质性肺疾病幸存者见于多数成人间质性肺疾病中心,仅少数继续在儿科中心随访。
- 幸存者肺功能显著受损,病因和治疗需求异质性对成人中心有实际影响。
- 转诊后重新指定诊断和治疗可能有助于精准和个体化管理。
研究设计与样本
- 欧洲研究,纳入34个成人和儿童间质性肺疾病中心。
- 报告2023年1月至7月儿童间质性肺疾病幸存者的新发/现患病例。
- 收集流行病学、临床、生理和遗传数据。
主要发现
- 共识别244例患者,中位诊断年龄12.5岁(IQR 6-16岁),入组时中位年龄25岁(IQR 22-33岁)。
- 51%为男性,86%不吸烟,中位FVC%预计值70%(IQR 47-89%),DLCO%预计值48%(IQR 32-75%)。
- 32%接受长期氧疗,227例(93%)在成人中心随访,17例(7%)从未转诊。
- 最常见诊断(82%)为儿童间质性肺疾病B1类35%、A4类21%、B2类14%、Bz类13%。
- Bz患者功能状态最差,60%患者仍在使用糖皮质激素。
关键数值与推荐
- 儿童间质性肺疾病B1类包括结节病、含铁血黄素沉着症、结缔组织病、血管炎,占35%。
- A4类为表面活性物质相关,占21%;B2类为闭塞性细支气管炎、过敏性肺炎,占14%;Bz类为未分类间质性肺疾病,占13%。
- 并非所有儿童间质性肺疾病诊断在成人间质性肺疾病分类中被识别。
临床怎么用
- 成人呼吸科应关注儿童间质性肺疾病幸存者的转诊随访,评估肺功能受损和长期氧疗需求。
- 对转诊患者考虑重新评估诊断和治疗方案,尤其是仍在使用糖皮质激素者。
- 注意儿童间质性肺疾病分类与成人分类的差异,避免漏诊或误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interstitial lung disease is rarer in children than adults, but, with increasing diagnostic awareness, more cases are being discovered. The prognosis of childhood interstitial lung disease is often poor, but increasing numbers are now surviving into adulthood. AIM: To characterise childhood interstitial lung disease survivors and identify their impact on adult interstitial lung disease centres. METHODS: This was a European study (34 adult and childhood interstitial lung disease centres) reporting incident/prevalent cases of childhood interstitial lung disease survivors from January to July 2023. Epidemiological, clinical, physiological and genetic data were collected. RESULTS: 244 patients were identified with a median (interquartile range) age at diagnosis of 12.5 years (6-16 years) and age at study inclusion of 25 years (22-33 years), with 51% male, 86% nonsmokers and a median (interquartile range) % predicted forced vital capacity of 70% (47-89%) and diffusing capacity of the lungs for carbon monoxide of 48% (32-75%). 32% were prescribed long-term oxygen and 227 (93%) were followed up in adult centres whereas 17 (7%) never transitioned. The commonest diagnoses (82%) were childhood interstitial lung disease category B1 (sarcoidosis, hemosiderosis, connective tissue disorders, vasculitis) at 35%, A4 (surfactant-related) at 21%, B2 (bronchiolitis obliterans, hypersensitivity pneumonitis) at 14% and Bz (unclassified interstitial lung disease) at 13%. Bz patients had the worst functional status. 60% of all patients were still being prescribed corticosteroids. Re-specification of diagnosis and treatment were made after transition for 9.8% and 16% of patients, respectively. Not all childhood interstitial lung disease diagnoses were recognised in adult interstitial lung disease classifications. CONCLUSION: Childhood interstitial lung disease survivors are seen in most adult interstitial lung disease centres and only a minority continue follow-up in paediatric centres. Survivors have a significant loss of lung function. The heterogeneity of their aetiologies and therapeutic requirements has a real impact on adult interstitial lung disease centres. Re-specification of diagnosis and treatment may contribute to precision and personalisation of management.
引用
- Manali ED, Griese M, Nathan N, et al. Childhood interstitial lung disease survivors in adulthood: a European collaborative study. Eur Respir J. 2025. PMID: 39638417. doi:10.1183/13993003.00680-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。